Oxytocin, Stress, Craving, Opioid Use Disorder

Oxytocin, Stress, Craving, Opioid Use Disorder

Publication date: Aug 09, 2019

Although stress has long been linked to substance use, craving and relapse, there are no available medications that target stress-induced substance use disorder (SUD). In particular, with the rise in opioid use, there is still a crucial need for developing effective pharmacological treatments that target and integrate the complexity of this disease. The long term goal of this project is to identify the key neuroendocrine pathways that are responsible for stress-induced craving in individuals with opioid use disorder (OUD) in order to better understand how they can be effectively treated.

Concepts Keywords
Addiction Addiction
ALT Naloxone
AST Oxytocin
Bilirubin Buprenorphine
Biobehavioral Drug rehabilitation
Birth Control Opioid antagonists
Blood Tertiary alcohols
Breastfeeding RTT
Buprenorphine Morphinans
Caffeine Organic compounds
Creatinine Clearance Drugs
Double Blind Opioids
DSM ORT
Electrolyte Abnormalities Birth control
Hormone History hypersensitivity
Hypersensitivity Disease
Informed Consent Current substance disorder
Interact
Intranasal
IU
Marijuana
Naloxone
Neuroendocrine
Neuron
Nicotine
Opiate
Opioid
Opioid Replacement Therapy
ORT
OSCO
Oxytocin
Pharmacological
Physical Examination
Placebo
Pregnancy
Prostaglandins
Randomized Trial
Relapse
Rhinitis
Stress
Urine
Vasoconstricting
Yohimbine

Semantics

Type Source Name
drug DRUGBANK Nicotine
drug DRUGBANK Medical Cannabis
disease MESH Suicide
drug DRUGBANK Creatinine
gene UNIPROT SLC17A5
drug DRUGBANK Naloxone
drug DRUGBANK Oxytocin
disease MESH relapse
disease MESH substance use disorder
drug DRUGBANK Tropicamide
drug DRUGBANK Buprenorphine
disease DOID rhinitis
disease MESH rhinitis
disease MESH abnormalities
disease DOID hypersensitivity
disease MESH hypersensitivity
drug DRUGBANK Caffeine

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *